A scalable human neuron model of Alzheimer's disease relevant tauopathy reveals mechanisms linking Tau fibrillization to synaptic dysfunction
Joanna LipkaiD, Xiwei ShaniD, Qiao Zhang, Przemysław DutkaiD, Lilian Phu, Matthew C Johnson, Timothy J. WendorffiD, Max AdrianiD, Anne BitoniD, Dawei SuniD, Meena ChoiiD, John G. Moffat, Alexis L. RohouiD, Alessandro OriiD, Céline EidenschenkiD, Zhixiang Tong, Casper C. HoogenraadiD, Claire G. JeongiD, Jasvinder K. AtwaliD
Abstract
Tauopathies, including Alzheimer's disease, are driven by pathological aggregation of hyperphosphorylated Tau, which disrupts synaptic integrity, impairs neuronal communication, and contributes to cognitive decline. To dissect tauopathy pathogenesis and enable therapeutic discovery, reliable and scalable human iPSC-neuron models are essential. Here, we developed two complementary iPSC-derived neuron models: an endogenous Tau seeding model, in which neurons are challenged with pre-formed Tau fragments that form paired helical filament (PHF)-consistent structures, and a Tau-0N3R overexpression seeding model to accelerate pathology. Both models recapitulate hallmark features of tauopathy, including the progressive formation of intracellular, hyperphosphorylated, sarkosyl-insoluble, and conformationally altered Tau aggregates (AT8, MC1 positive), along with synaptic and neuronal dysfunction. Cryogenic electron tomography (cryo-ET) further revealed the morphology of Tau fibrils within cells, as well as the ultrastructure of Tau fibrils trapping synaptic vesicles in situ. Using this platform, we performed integrated phosphoproteomics, high-content screening, and functional validation to identify key pathways driving Tau aggregation. MARK2-mediated phosphorylation within Tau's microtubule-binding domain emerged as an early trigger of aggregation, confirmed by site-specific mutagenesis. In parallel, small molecules targeting the PI3K/mTOR/GSK3 pathway reduced aggregation and restored synaptic function, with GSK3 inhibition lowering phosphorylation at critical aggregation-driving sites on Tau. Together, these findings establish a physiologically relevant, scalable platform for therapeutic screening that connects Tau seed uptake, site-specific phosphorylation, fibril formation, and synaptic disruption, ultimately identifying mechanistically separable intervention points along the aggregation cascade.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TNFα-driven Aβ aggregation, synaptic dysfunction and hypermetabolism in human iPSC-derived cortical neurons
Alicia González Díaz, Elisa Belli, … Michele Vendruscolo·bioRxiv·Aug 30, 2024
- Early synaptic pathology is associated with small tau aggregates in Alzheimer's disease
Emre Fertan, Shekhar Kedia, … David Klenerman·Acta NeuropathologicaPeer-reviewed·Jan 23, 2026
- Seeding patient-derived tau induces tauopathy-specific aggregation and lysosomal disruption in human cells
Tomas Kavanagh, Aysha Y. G. Strobbe, … Eleanor Drummond·bioRxiv·Apr 21, 2026
- Patient-derived tau-seeded human neuronal chimeras recapitulate mature Alzheimer's tau pathology and uncover human-specific neuronal vulnerability
Yanru Ji, Purba Mandal, … Ranjie Xu·bioRxiv·Jul 9, 2026
- Subcellular proteomics and iPSC modeling uncover reversible mechanisms of axonal pathology in Alzheimer's disease
Yifei Cai, Jean E. Kanyo, … Jaime Grutzendler·Nature AgingPeer-reviewed·Mar 10, 2025
- Tau aggregate replication occurs at the pre-synapse of cultured human neurons and increases with application of TNFa
Shekhar Kedia, Emre Fertan, … David Klenerman·bioRxiv·Jun 3, 2026